Marc Belsky Biography and Net Worth

CFO & Sec. of Kezar Life Sciences

Marc L. Belsky has served as our Chief Financial Officer and secretary since April 2018. Prior to joining us, from October 2009 to April 2018, Mr. Belsky held several roles at Five Prime Therapeutics, Inc., a publicly held biopharmaceutical company, including most recently as Senior Vice President and Chief Financial Officer. Before that, Mr. Belsky served in various roles at Cell Genesys, Inc., a biotechnology company acquired by BioSante Pharmaceuticals, Inc., Active Aero Group, Inc., DataWave Systems Inc., and Michigan National Corporation, a holding company for Michigan National Bank, which was acquired by BANA Holding Corporation. Mr. Belsky started his career as an auditor with Coopers & Lybrand.

Mr. Belsky received a Bachelor of Science degree in accounting from Wayne State University and a Master of Business Administration degree from the University of Michigan. He is also a certified public accountant.

How old is Marc L. Belsky?: Mr. Belsky is currently 69 years old. There are 3 older executives and no younger executives at Kezar Life Sciences. Learn More on Marc L. Belsky's age.
How do I contact Marc L. Belsky?: The corporate mailing address for Mr. Belsky and other Kezar Life Sciences executives is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Kezar Life Sciences can also be reached via phone at (650) 822-5600 and via email at [email protected]. Learn More on Marc L. Belsky's contact information.
Has Marc L. Belsky been buying or selling shares of Kezar Life Sciences?: Marc L. Belsky has not been actively trading shares of Kezar Life Sciences over the course of the past ninety days. Learn More on Marc L. Belsky's trading history.
Who are Kezar Life Sciences' active insiders?: Kezar Life Sciences' insider roster includes Marc Belsky (CFO & Sec. ), John Fowler (Co-Founder), and Michael Kauffman (Director). Learn More on Kezar Life Sciences' active insiders.
Are insiders buying or selling shares of Kezar Life Sciences?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 668 shares worth more than $3,874.40. The most recent insider tranaction occured on July, 2nd when insider Mark C Schiller sold 668 shares worth more than $3,874.40. Insiders at Kezar Life Sciences own 9.3% of the company. Learn More about insider trades at Kezar Life Sciences.
Information on this page was last updated on 7/2/2024.

Marc L. Belsky Insider Trading History at Kezar Life Sciences

Marc L. Belsky Buying and Selling Activity at Kezar Life Sciences

Kezar Life Sciences Company Overview

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Today's Range

Now: $7.50

$7.41

$7.60

50 Day Range

MA: $7.38

$5.29

$8.95

2 Week Range

Now: $7.50

$5.20

$11.35

Volume

46,006 shs

Average Volume

73,752 shs

Market Capitalization

$54.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>